Introduction
============

Retinal vein occlusions are a frequent cause of visual loss, and approximately 16 million adults worldwide are affected.[@b1-opth-5-1509] Macular edema and retinal ischemia are the primary sources of visual impairment in these settings. Retinal vein occlusions can be classified as branch retinal vein occlusion, hemiretinal vein occlusion, and central retinal vein occlusion depending on the occlusion site. Risk factors for the development of a retinal vein occlusion include diabetes mellitus, hypertension, hyperlipidemia, atherosclerosis, glaucoma, and smoking.[@b2-opth-5-1509]

The clinical course and visual prognosis of retinal vein occlusions can be highly variable. Clinical trials have evaluated treatment modalities including observation, laser, intravitreal triamcinolone, and anti-vascular endothelial growth factor (VEGF) therapy. Intravitreal bevacizumab, an anti-VEGF drug, has been used to treat a variety of vitreoretinal diseases. Rosenfeld et al first injected intravitreal bevacizumab for macular edema from a central retinal vein occlusion and also reported long-term improvements in visual acuity and optical coherence tomography (OCT, Carl Zeiss Meditec, Jena, Germany) being sustained through one year with treatment.[@b3-opth-5-1509],[@b4-opth-5-1509] More recently, randomized, controlled clinical trials have evaluated the frequency of treatment with anti-VEGF therapy for macular edema secondary to retinal vein occlusions to help determine optimal long-term therapeutic strategies.[@b5-opth-5-1509],[@b6-opth-5-1509]

We describe a case of an acute hemiretinal vein occlusion with confluent macular hemorrhage and persistent macular edema for which early and continued treatment with intravitreal bevacizumab facilitated functional and structural improvement and resolution.

Case report
===========

A 39-year-old male with no significant past medical history presented with decreased vision in the left eye for six weeks. The patient was initially evaluated at an outside facility and diagnosed with a hemiretinal vein occlusion in the left eye. Medical and hypercoaguable laboratory evaluation was unremarkable, and the patient was referred to the Bascom Palmer Eye Institute. Best corrected visual acuity was 20/20 in the right eye and 20/80 in the left eye. Intraocular pressures were 18 and 17 mmHg in the right and left eye, respectively. External and slit lamp examinations were unremarkable. Fundus evaluation of the right eye was within normal limits, and the left eye demonstrated extensive, confluent intraretinal hemorrhages extending inferiorly from the nerve and involving the macula ([Figure 1A](#f1-opth-5-1509){ref-type="fig"}). OCT of the right eye was unremarkable, and the left eye demonstrated intraretinal and subretinal fluid with a central retinal thickness of 696 microns ([Figure 1B](#f1-opth-5-1509){ref-type="fig"}). Fluorescein angiography of the left eye showed blockage from hemorrhage, with subsequent limited assessment of perfusion and late hyperfluorescence ([Figure 1C--E](#f1-opth-5-1509){ref-type="fig"}). The patient was treated with 1.25 mg of intravitreal bevacizumab at this visit. At one month, visual acuity in the left eye improved to 20/60 and OCT demonstrated improved fluid with a central retinal thickness of 534 microns ([Figure 2A](#f2-opth-5-1509){ref-type="fig"}). The patient was retreated with intravitreal bevacizumab. At the subsequent four-week visit, the patient was symptomatic with a decline in visual acuity to 20/70 and increased fluid was present on OCT ([Figure 2B](#f2-opth-5-1509){ref-type="fig"}). The patient was treated with a third intravitreal bevacizumab injection. Six weeks later, visual acuity improved to 20/40, the confluent macular hemorrhage had improved, and OCT showed reduced fluid ([Figure 2C and D](#f2-opth-5-1509){ref-type="fig"}). Treatment was continued at this visit, and at six-week intervals due to persistent visual symptoms and macular edema and hemorrhage. The patient received a total of nine intravitreal bevacizumab injections. At recent follow-up, six weeks after the last injection, visual acuity improved to 20/25 and fundus evaluation showed minimal intraretinal hemorrhages ([Figure 3A](#f3-opth-5-1509){ref-type="fig"}). OCT demonstrated a preserved foveal contour with resolved fluid and subfoveal inner and outer segment (IS/OS) disruption ([Figure 3B](#f3-opth-5-1509){ref-type="fig"}). The patient was observed.

Discussion
==========

Macular edema is often a frequent cause of vision loss in patients with retinal vein occlusions. Since hemiretinal vein occlusions share etiologic and clinical features of both branch and central retinal vein occlusions, treatment strategies are often extrapolated from studies pertaining to these conditions. The Branch Vein Occlusion Study (BVOS) reported that laser photocoagulation is beneficial for perfused macular edema with \<20/40 vision for at least three months, but the visual recovery is both slow and limited.[@b7-opth-5-1509] After three years of follow- up, 63% of laser treated eyes improved ≥2 lines of vision compared with 36% of control eyes.[@b7-opth-5-1509] The average improvement of visual acuity was only 1.3 lines from the baseline in the laser-treated group, and 40% of eyes had a visual acuity of ≤20/40 and 12% had a visual acuity of \<20/200.[@b7-opth-5-1509] Based on the Central Retinal Vein Occlusion Study (CVOS) results, grid laser photocoagulation is not a recommended therapy for improving visual acuity from macular edema secondary to central retinal vein occlusion.[@b8-opth-5-1509] The Standard Care versus Corticosteroid for Retinal Vein Occlusion (SCORE) study group concluded that 1 mg intravitreal triamcinolone, with retreatment criteria as utilized in the trial, was superior to observation and could be considered up to one year for central retinal vein occlusion-related macular edema, and was equivalent to macular grid laser treatment for macular edema from a branch retinal vein occlusion ([Tables 1](#t1-opth-5-1509){ref-type="table"} and [2](#t2-opth-5-1509){ref-type="table"}).[@b9-opth-5-1509],[@b10-opth-5-1509] This was the first trial to demonstrate efficacy of a treatment for macular edema secondary to a central retinal vein occlusion. Further, the Ozurdex Geneva Study Group investigated the efficacy of a dexamethasone intravitreal implant, Ozurdex^®^, for the treatment of macular edema due to retinal vein occlusions. The proportion of eyes achieving at least a 15-letter improvement from baseline was significantly greater in the 0.35 mg and 0.7 mg implant groups from day 30; but this effect was not maintained by day 180, when no statistically significant difference from the sham group was observed ([Tables 1](#t1-opth-5-1509){ref-type="table"} and [2](#t2-opth-5-1509){ref-type="table"}).[@b11-opth-5-1509] However, associated risks of intraocular pressure elevation and cataracts with steroid treatment were present in both studies.

Additional therapeutic modalities have also been explored in the treatment of macular edema from retinal vein occlusions. VEGF-A has been implicated as a major factor for increased vascular permeability, and elevated intravitreal VEGF levels have been reported to be significantly increased after retinal vein occlusions and correlate with the degree of macular edema.[@b12-opth-5-1509] VEGF also stimulates endothelial cell hypertrophy, which reduces capillary lumen size and may lead to retinal ischemia.[@b13-opth-5-1509] Bevacizumab is a full length monoclonal humanized antibody to all active isoforms of vascular endothelial growth factor, and is frequently used in clinical practice to treat macular edema from retinal vein occlusions. Recently, clinical studies have demonstrated beneficial effects of monthly intravitreal treatment with an anti-VEGF agent, ranibizumab, on both macular edema and visual acuity in patients with retinal vein occlusions. Data from the Phase III Study of the Efficacy and Safety of Ranibizumab Injection in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO) and the Study of the Efficacy and Safety of Ranibizumab Injection in Patients with Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE) demonstrated that a higher proportion of patients treated with ranibizumab 0.3 mg and 0.5 mg experienced significant improvements in visual acuity and central foveal thickness at six months following monthly dosing compared with patients who received sham injections ([Tables 1](#t1-opth-5-1509){ref-type="table"}, [2](#t2-opth-5-1509){ref-type="table"}, and [3](#t3-opth-5-1509){ref-type="table"}).[@b5-opth-5-1509],[@b6-opth-5-1509] These improvements were sustained at 12 months in both trials in the ranibizumab groups, following six months of as-needed treatment ([Table 3](#t3-opth-5-1509){ref-type="table"}).[@b5-opth-5-1509],[@b6-opth-5-1509] Overall, results from these studies demonstrate that regular, monthly anti-VEGF treatment for retinal vein occlusions provided improvements superior to previous treatment modalities.

In the current report, a young patient with decreased visual acuity and extensive macular hemorrhage with macular edema demonstrated an initial and ongoing functional and structural improvement with continued intravitreal bevacizumab treatment. Initial visual acuity, younger age, duration of retinal vein occlusion, baseline central retinal thickness, response to the first injection, and integrity of the photoreceptors have all been reported to be predictive factors for response to anti-VEGF therapy.[@b14-opth-5-1509],[@b15-opth-5-1509] Although this patient returned to his baseline vision, the presence of subfoveal IS/OS disruption likely secondary to chronic macular edema and/or initial hemorrhage may also indicate that ongoing treatment with intravitreal bevacizumab prevented further destructive changes and a subsequent decline in vision. The Patterns and Trends Survey by the American Society of Retina Specialists showed that approximately 50% of respondents use intravitreal bevacizumab as first-line therapy for retinal vein occlusions.[@b16-opth-5-1509] The favorable treatment outcome for this patient lends support to the clinical impression that regular injections of intravitreal bevacizumab are an effective primary treatment strategy for persistent macular edema and hemorrhage from a hemiretinal vein occlusion.
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![Initial presentation. Best corrected visual acuity 20/80. (**A**) Color fundus photograph demonstrates extensive, confluent inferior retinal hemorrhages with macular involvement. (**B**) Optical coherence tomography demonstrates intraretinal cysts and subretinal fluid. Central foveal thickness 696 microns (central 1 mm subfield). (**C**--**E**) Fluorescein angiography. (**C**) Early: 28 seconds, (**D**) 2.37 minutes, and (**E**) Late: 9.42 minutes, extensive blockage from hemorrhage and late hyperfluorescence.](opth-5-1509f1){#f1-opth-5-1509}

![Cirrus spectral domain optical coherence tomography progression. (**A**) Best corrected visual acuity 20/60, improved intraretinal and subretinal fluid (central foveal thickness 534 microns) after initial intravitreal bevacizumab injection four weeks earlier. (**B**) Best corrected visual acuity 20/70, central foveal thickness 682 microns. (**C**) Color fundus photograph six weeks after third intravitreal bevacizumab injection. Improved confluent macular hemorrhage. (**D**) Best corrected visual acuity 20/40, central foveal thickness 473 microns, corresponding optical coherence tomography to (**C**) visit.](opth-5-1509f2){#f2-opth-5-1509}

![Recent follow-up. Best corrected visual acuity 20/25. (**A**) Color fundus photograph demonstrates resolution of majority of confluent hemorrhages. (**B**) Optical coherence tomography demonstrates resolved fluid (central foveal thickness 261 microns) and presence of subfoveal inner and outer segment disruption.](opth-5-1509f3){#f3-opth-5-1509}

###### 

Branch retinal vein occlusion summary data[@b5-opth-5-1509],[@b9-opth-5-1509],[@b10-opth-5-1509]

  Treatment                       Months   BCVA change^a^   ≥15 letters^a^   CFT change
  ------------------------------- -------- ---------------- ---------------- --------------
  Triamcinolone 1 mg (SCORE)      12       +5.7             26%              −149 microns
  Dexamethasone 0.7 mg (GENEVA)   6        +7.4             22%              −119 microns
  Ranibizumab 0.5 mg (BRAVO)      12       +18.3            60%              −347 microns

**Abbreviations:** BCVA, best corrected visual acuity; CFT, central foveal thickness.

###### 

Central retinal vein occlusion summary data[@b6-opth-5-1509],[@b9-opth-5-1509],[@b10-opth-5-1509]

  Treatment                       Months   BCVA change[a](#tfn2-opth-5-1509){ref-type="table-fn"}   ≥15 letters[a](#tfn2-opth-5-1509){ref-type="table-fn"}   CFT change
  ------------------------------- -------- -------------------------------------------------------- -------------------------------------------------------- --------------
  Triamcinolone 1 mg (SCORE)      12       −1.2                                                     27%                                                      −196 microns
  Dexamethasone 0.7 mg (GENEVA)   6        +0.1                                                     22%                                                      −119 microns
  Ranibizumab 0.5 mg (CRUISE)     12       +13.9                                                    51%                                                      −462 microns

**Note:** ETDRS letters.

**Abbreviations:** BCVA, change in best corrected visual acuity; CFT, change in central foveal thickness; EDTRS, Early Treatment for Diabetic Retinopathy Study.

###### 

Outcomes in BCVA and CFT after 6 and 12 months of ranibizumab 0.5 mg treatment in BRAVO and CRUISE studies[@b5-opth-5-1509],[@b6-opth-5-1509]

  Study    Mean change from baseline BCVA[a](#tfn4-opth-5-1509){ref-type="table-fn"} 0.5 mg at 6 months versus sham   Mean change from baseline CFT, μm at 6 months versus sham   Mean change from baseline BCVA[a](#tfn4-opth-5-1509){ref-type="table-fn"} 0.5 mg at 12 months versus sham   Mean change from baseline CFT, μm at 12 months versus sham
  -------- ---------------------------------------------------------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ------------------------------------------------------------
  BRAVO    +18.3 versus +7.3                                                                                          −345.2 versus −157.7                                        +18.3 versus +12.1                                                                                          −374.4 versus −273.4
  CRUISE   +14.9 versus +0.8                                                                                          −452.3 versus −167.7                                        +13.9 versus +7.3                                                                                           −462.1 versus −427.2

**Note:** ETDRS letters. Patients were randomized 1:1:1 to receive sham injections or ranibizumab in one of two doses (0.3 or 0.5 mg) in both studies.

**Abbreviations:** BCVA, best corrected visual acuity; CFT, central foveal thickness; ETDRS, Early Treatment for Diabetic Retinopathy Study.
